Literature DB >> 29439186

Severe hemolysis and transfusion reactions after treatment with BGB-3111 and PD-1 antibody for Waldenström macroglobulinemia.

Jad Othman1, Emma Verner1, Constantine S Tam2,3,4, Jane Huang5, Leo Lin5, James Hilger5, Judith Trotman1,6, Robin Gasiorowski7,6.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29439186      PMCID： PMC5927990          DOI： 10.3324/haematol.2017.186817

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  9 in total

Review 1.  Autoimmune manifestations in patients with Waldenström macroglobulinemia.

Authors:  Bruno Bockorny; Jonessa A Atienza; Constantin A Dasanu
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2014-06-10

2.  Immunotherapy-Associated Hemolytic Anemia with Pure Red-Cell Aplasia.

Authors:  Ranjit Nair; Shereen Gheith; Suresh G Nair
Journal:  N Engl J Med       Date:  2016-03-17       Impact factor: 91.245

3.  Ibrutinib in previously treated Waldenström's macroglobulinemia.

Authors:  Steven P Treon; Christina K Tripsas; Kirsten Meid; Diane Warren; Gaurav Varma; Rebecca Green; Kimon V Argyropoulos; Guang Yang; Yang Cao; Lian Xu; Christopher J Patterson; Scott Rodig; James L Zehnder; Jon C Aster; Nancy Lee Harris; Sandra Kanan; Irene Ghobrial; Jorge J Castillo; Jacob P Laubach; Zachary R Hunter; Zeena Salman; Jianling Li; Mei Cheng; Fong Clow; Thorsten Graef; M Lia Palomba; Ranjana H Advani
Journal:  N Engl J Med       Date:  2015-04-09       Impact factor: 91.245

4.  Autoimmune hemolytic anemia after nivolumab treatment in Hodgkin lymphoma responsive to immunosuppressive treatment. A case report.

Authors:  Magalie P Tardy; Lauris Gastaud; Annick Boscagli; Frederic Peyrade; Andrea Gallamini; Antoine Thyss
Journal:  Hematol Oncol       Date:  2016-08-19       Impact factor: 5.271

5.  Autoimmune hemolytic anemia induced by anti-PD-1 therapy in metastatic melanoma.

Authors:  Benjamin Y Kong; Kenneth P Micklethwaite; Sanjay Swaminathan; Richard F Kefford; Matteo S Carlino
Journal:  Melanoma Res       Date:  2016-04       Impact factor: 3.599

Review 6.  Immune-related adverse events with immune checkpoint blockade: a comprehensive review.

Authors:  J M Michot; C Bigenwald; S Champiat; M Collins; F Carbonnel; S Postel-Vinay; A Berdelou; A Varga; R Bahleda; A Hollebecque; C Massard; A Fuerea; V Ribrag; A Gazzah; J P Armand; N Amellal; E Angevin; N Noel; C Boutros; C Mateus; C Robert; J C Soria; A Marabelle; O Lambotte
Journal:  Eur J Cancer       Date:  2016-01-05       Impact factor: 9.162

7.  Autoimmune Hemolytic Anemia as a Complication of Nivolumab Therapy.

Authors:  Amruth R Palla; Devin Kennedy; Hossain Mosharraf; Donald Doll
Journal:  Case Rep Oncol       Date:  2016-11-07

8.  Immunotherapy-associated autoimmune hemolytic anemia.

Authors:  Uqba Khan; Farman Ali; Muhammad Siddique Khurram; Awais Zaka; Tarik Hadid
Journal:  J Immunother Cancer       Date:  2017-02-21       Impact factor: 13.751

9.  Development of Hemolytic Anemia in a Nivolumab-Treated Patient with Refractory Metastatic Squamous Cell Skin Cancer and Chronic Lymphatic Leukemia.

Authors:  K S Schwab; A Heine; T Weimann; G Kristiansen; P Brossart
Journal:  Case Rep Oncol       Date:  2016-06-27
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.